Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) expands its research agreement with Genentech for its drug delivery technology, DEP
- The initial agreement was signed in December 2021 and involves Starpharma designing and synthesising dendrimer-based drug conjugates for Genentech to test and characterise
- The expanded program includes additional drug conjugates with no changes to the original agreement terms
- Throughout the partnership, Starpharma will receive research fees which are not expected to be material and there are also no material costs to Starpharma
- SPL shares are down 5.56 per cent and trading at 68 cents at 12:28 pm AEST
Starpharma (SPL) has expanded its research agreement with Genentech for its drug delivery technology, DEP.
Genentech is a member of the Swiss multinational healthcare company, Roche Group and is working with Starpharma to evaluate DEP, dendrimer-based drug conjugates.
Under the agreement, Starpharma designs and synthesises the conjugates which are passed on to Genentech for testing and characterisation.
The initial research program was signed in December 2021 and has now been expanded to include additional DEP drug conjugates, with no changes to the agreement terms.
Throughout the partnership, Starpharma will receive research fees which are not expected to be material. There are also no material costs to Starpharma.
The dendrimer-based DEP platform reportedly enhances the therapeutic utility of drugs through improved solubility, efficacy and pharmacokinetic control.
In addition to the agreement with Genentech, SPL also has partnerships with international pharmaceutical and biotechnology companies, including AstraZeneca, Merck & Co, and Chase Sun.
SPL shares were down 5.56 per cent, trading at 68 cents at 12:28 pm AEST.
